Lara Hathout

Dr. Lara Hathout

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
LHLara Hathout
Lara Hathout
MFMichael R. Folkert
Michael R. Folkert
MKMarisa A. Kollmeier
Marisa A. Kollmeier
YYYoshiya Yamada
Yoshiya Yamada
GCGil'AD N. Cohen
Gil'AD N. Cohen
MZMichael J. Zelefsky
Michael J. Zelefsky

1 September 2011 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MJMarjory Jolicoeur
Marjory Jolicoeur
MRMarie-Lynn Racine
Marie-Lynn Racine
ITIsabelle Trop
Isabelle Trop
LHLara Hathout
Lara Hathout
DNDavid Nguyen
David Nguyen
SDSandrine David
Sandrine David

1 April 2018 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Closed access
PDF file
LHLara Hathout
Lara Hathout
NMNell Maloney-Patel
Nell Maloney-Patel
UMUsha Malhotra
Usha Malhotra
SWShang-Jui Wang
Shang-Jui Wang
SCSita Chokhavatia
Sita Chokhavatia
SJSalma K. Jabbour
Salma K. Jabbour
Colorectal cancer incidence and death rates have been declining over the past 10 years. However, it remains the second leading cause of death in men ages 60–79 and the third leading cause of death in men over 80 and in women over 60 years old. However, there is little data specific to the treatment of the elder patient, since few of these patients are included in trials. With the advent of improved therapies, there are many alternative options available. Still, no definitive consensus or guidelines have been defined for this particular patient population. The goal of this study is to review the literature on the management of rectal cancer in the elderly and to propose treatment algorithms to help the oncology team in treatment decision-making.

1 December 2013 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
LHLara Hathout
Lara Hathout
THTarek Hijal
Tarek Hijal
VTValérie Théberge
Valérie Théberge
BFBernard Fortin
Bernard Fortin
HVHoria Vulpe
Horia Vulpe
MYMichael Yassa
Michael Yassa

1 March 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SWShang-Jui Wang
Shang-Jui Wang
LHLara Hathout
Lara Hathout
UMUsha Malhotra
Usha Malhotra
NMNell Maloney-Patel
Nell Maloney-Patel
SKSarah Kilic
Sarah Kilic
SJSalma Jabbour
Salma Jabbour

1 October 2019 in Advances in Radiation Oncology
Verified
Journal Article
Open access
LHLara Hathout
Lara Hathout
OMOmar Mahmoud
Omar Mahmoud
YWYaqun Wang
Yaqun Wang
IVIrina Vergalasova
Irina Vergalasova
MBMaroie Barkati
Maroie Barkati
EVEric Vigneault
Eric Vigneault
To compare health-related quality of life (HRQOL) of high-dose-rate brachytherapy (HDRB) versus low dose-rate brachytherapy (LDRB) for localized prostate cancer in a multi-institutional phase 2 randomized trial. Men with favorable-risk prostate cancer were randomized between monotherapy brachytherapy with either Iodine-125 LDRB to 144 Gy or single-fraction Iridium-192 HDRB to 19 Gy. HRQOL and urinary toxicity were recorded at baseline and at 1, 3, 6, and 12 months using the Expanded Prostate Cancer Index Composite (EPIC)-26 scoring and the International Prostate Symptom Score (IPSS). Independent samples t test and mixed effects modeling were performed for continuous variables. Time to IPSS resolution, defined as return to its baseline score ±5 points, was calculated using Kaplan-Meier estimator curves with the log-rank test. A multiple-comparison adjusted P value of ≤.05 was considered significant. LDRB and HDRB were performed in 15 and 16 patients, respectively, for a total of 31 patients. At 3 months, patients treated with LDRB had a higher IPSS score (mean, 15.5 vs 6.0, respectively; P = .003) and lower EPIC urinary irritative score (mean, 69.2 vs 85.3, respectively; P = .037) compared with those who received HDRB. On repeated measures at 1, 3, 6, and 12 months, the IPSS (P = .003) and EPIC urinary irritative scores (P = .019) were significantly better in the HDR arm, translating into a lower urinary toxicity profile. There were no significant differences in the EPIC urinary incontinence, sexual, or bowel habit scores between the 2 groups at any measured time point. Time to IPSS resolution was significantly shorter in the HDRB group (mean, 2.0 months) compared with the LDRB group (mean, 6.0 months; P = .028). HDRB monotherapy is a promising modality associated with a lower urinary toxicity profile and higher HRQOL in the first 12 months compared with LDRB.